Myriad Genetics Inc (MYGN)

$8.15 +0.10 (1.24%)
Market Cap 758.32M
Revenue (ttm) 837.60M
Net Income (ttm) -127.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.20%
Debt to Equity Ratio 0.15
Volume 767,000
Avg Vol 1,281,548
Day's Range N/A - N/A
Shares Out 93.05M
Stochastic %K 55%
Beta 1.97
Analysts Sell
Price Target $7.68

Company Profile

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 801 584 3600
Fax: 801 584 3640
Address:
322 North 2200 West, Salt Lake City, United States
SilentMove
SilentMove Oct. 5 at 1:05 PM
$MYGN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
PeakedSeller
PeakedSeller Oct. 3 at 8:15 PM
$MYGN $MYGN closed $8.06. Hold $7.85–8.00 and $8.20 → $8.8–9.2 is next; clear that and $10 stays live into Q3. Fundamentals still backing it (guide up, ~70% GM, EBITDA +). 📈
0 · Reply
TradingUK
TradingUK Oct. 3 at 2:26 PM
$MYGN Sold the remainder of my position today from an average of 4.80
2 · Reply
PeakedSeller
PeakedSeller Sep. 29 at 7:12 PM
$MYGN red on a green tape = profit-taking after first tag of $8. Watch $7.15–7.20 hold; reclaim $7.50 and the run at $8.8–$9.2 stays on deck. Fundamentals unchanged. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 23 at 2:52 PM
$MYGN $MYGN x $SOPH = global liquid-biopsy CDx build (MSK-ACCESS). Strategic win (US regs + 800-site ex-US network), but no $$ today—so fade. Hold $7.5, push >$8.05, and $8.8–$9.2 stays on deck into Q3.
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:55 PM
$MYGN this stock is only in the first steps of their redemption story. By the end of next year this company will get back to >20$ a share. By the end of this year I fully expect $10-12 per share after inline q3 results and continued optimism around pipeline and mental health testing growth
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:53 PM
$MYGN fully expecting a move to >15$ a share by year end with data read outs and FDA filings this year. Cash runway into 2028 with no current debt burden and cash worth more than 3x their current market cap
1 · Reply
PeakedSeller
PeakedSeller Sep. 16 at 6:04 PM
$MYGN
0 · Reply
d00bie
d00bie Sep. 16 at 4:53 PM
$MYGN back to $13-$14 any day now
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 12:40 PM
$MYGN down 74.5% in a year — is the decline overdone? 🤔 📉 Facing fierce competition and macro pressures 🧬 Yet, expanding in Oncology with innovative tests like Precise MRD Opportunity or trap? Full analysis here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-body-12548&ADID=SYND_STOCKTWITS_TWEET_2_2751944_BODY_12548
0 · Reply
Latest News on MYGN
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 14, 2025, 8:00 AM EDT - 11 days ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Oct 8, 2025, 5:21 PM EDT - 17 days ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:01 AM EDT - 4 weeks ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:00 AM EDT - 4 weeks ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:06 AM EDT - 6 weeks ago

Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 7:00 PM EDT - 7 weeks ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Sep 3, 2025, 4:30 PM EDT - 7 weeks ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 18, 2025, 8:30 AM EDT - 2 months ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 13, 2025, 8:00 AM EDT - 2 months ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 6, 2025, 5:51 PM EDT - 2 months ago

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:14 AM EDT - 2 months ago

Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Jun 3, 2025, 9:00 AM EDT - 5 months ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 4:05 PM EDT - 5 months ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

May 26, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

May 25, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 10:00 AM EDT - 5 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

May 20, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

May 19, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

May 16, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

May 15, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025, 4:45 PM EDT - 5 months ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

May 14, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 5 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation

May 12, 2025, 7:15 PM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:35 PM EDT - 6 months ago

Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 6, 2025, 4:05 PM EDT - 6 months ago

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

Myriad Genetics: Significantly Undervalued With Profitability In Sight

May 2, 2025, 12:58 AM EDT - 6 months ago

Myriad Genetics: Significantly Undervalued With Profitability In Sight

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Apr 30, 2025, 8:00 AM EDT - 6 months ago

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 6 months ago

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 21, 2025, 4:05 PM EDT - 6 months ago

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Myriad Genetics Announces Inducement Awards

Apr 8, 2025, 4:15 PM EDT - 7 months ago

Myriad Genetics Announces Inducement Awards

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Apr 7, 2025, 8:00 AM EDT - 7 months ago

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Feb 25, 2025, 2:22 PM EST - 8 months ago

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

UNH

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 8:03 PM EST - 8 months ago

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript

SilentMove
SilentMove Oct. 5 at 1:05 PM
$MYGN Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
PeakedSeller
PeakedSeller Oct. 3 at 8:15 PM
$MYGN $MYGN closed $8.06. Hold $7.85–8.00 and $8.20 → $8.8–9.2 is next; clear that and $10 stays live into Q3. Fundamentals still backing it (guide up, ~70% GM, EBITDA +). 📈
0 · Reply
TradingUK
TradingUK Oct. 3 at 2:26 PM
$MYGN Sold the remainder of my position today from an average of 4.80
2 · Reply
PeakedSeller
PeakedSeller Sep. 29 at 7:12 PM
$MYGN red on a green tape = profit-taking after first tag of $8. Watch $7.15–7.20 hold; reclaim $7.50 and the run at $8.8–$9.2 stays on deck. Fundamentals unchanged. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 23 at 2:52 PM
$MYGN $MYGN x $SOPH = global liquid-biopsy CDx build (MSK-ACCESS). Strategic win (US regs + 800-site ex-US network), but no $$ today—so fade. Hold $7.5, push >$8.05, and $8.8–$9.2 stays on deck into Q3.
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:55 PM
$MYGN this stock is only in the first steps of their redemption story. By the end of next year this company will get back to >20$ a share. By the end of this year I fully expect $10-12 per share after inline q3 results and continued optimism around pipeline and mental health testing growth
0 · Reply
PeakedSeller
PeakedSeller Sep. 19 at 4:53 PM
$MYGN fully expecting a move to >15$ a share by year end with data read outs and FDA filings this year. Cash runway into 2028 with no current debt burden and cash worth more than 3x their current market cap
1 · Reply
PeakedSeller
PeakedSeller Sep. 16 at 6:04 PM
$MYGN
0 · Reply
d00bie
d00bie Sep. 16 at 4:53 PM
$MYGN back to $13-$14 any day now
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 12:40 PM
$MYGN down 74.5% in a year — is the decline overdone? 🤔 📉 Facing fierce competition and macro pressures 🧬 Yet, expanding in Oncology with innovative tests like Precise MRD Opportunity or trap? Full analysis here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-body-12548&ADID=SYND_STOCKTWITS_TWEET_2_2751944_BODY_12548
0 · Reply
ZacksResearch
ZacksResearch Sep. 16 at 11:40 AM
$MYGN — growth story or dead weight? The company is expanding oncology testing and rolling out new diagnostics, but inflation and rising competition are clouding the outlook. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2751944/is-it-a-prudent-move-to-retain-mygn-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2751944-teaser-12547&ADID=SYND_STOCKTWITS_TWEET_2_2751944_TEASER_12547
0 · Reply
PeakedSeller
PeakedSeller Sep. 11 at 9:57 PM
$MYGN closed $7.68—breakout held. Next gates $7.95–$8.20 then $8.8–$9.2. Strategy & margins intact (guide up, ~70% GM, EBITDA +). $9–10 into Q3 very much alive. 📈
0 · Reply
PeakedSeller
PeakedSeller Sep. 11 at 6:56 PM
$MYGN clear breakout🙌🏻
0 · Reply
ZacksResearch
ZacksResearch Sep. 8 at 12:19 PM
$MYGN — After a 75.5% plunge over the past year, is there a turnaround in sight? 🔍 🧬 New Phase 2 trial shows promise for Myriad Genetics' Precise MRD in ccRCC. The trial indicated that patients with low ctDNA levels might delay systemic treatments, potentially sparing them from side effects. 📉 Despite recent news, shares dropped 2.7%, but a strong Oncology expansion strategy could shift market sentiment. Discover what could drive MYGN's recovery 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-body-11229&ADID=SYND_STOCKTWITS_TWEET_2_2747817_BODY_11229
0 · Reply
ZacksResearch
ZacksResearch Sep. 8 at 11:19 AM
$MYGN could be setting up for a breakout 🚀 The Lancet just backed its Precise MRD with strong ctDNA detection results in oligometastatic ccRCC — a big validation for its oncology growth strategy. Full breakdown here 👉 https://www.zacks.com/stock/news/2747817/mygn-stock-might-gain-on-the-lancet-study-backing-precise-mrd?cid=sm-stocktwits-2-2747817-teaser-11228&ADID=SYND_STOCKTWITS_TWEET_2_2747817_TEASER_11228
0 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:08 PM
$MYGN New meta-analysis (JCP) shows GeneSight improves remission +41% and response +30% vs TAU (n=3,532). Co confirms it’ll submit to payers. With price above $6.9, eyes on $7.5–8.2 next; clean Q3 keeps $9–10 in play. 📈🔬
0 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:02 PM
$MYGN https://investor.myriad.com/news-releases/news-release-detail/26641/
2 · Reply
PeakedSeller
PeakedSeller Sep. 5 at 7:01 PM
$MYGN https://investor.myriad.com/news-releases/news-release-detail/26656/
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 4:59 PM
$MYGN breakthrough in depression treatment — stock momentum next? 🚀 GeneSight just proved superior to treatment-as-usual in major depression, a result that could fuel wider adoption and investor interest. Full breakdown here 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-teaser-11205&ADID=SYND_STOCKTWITS_TWEET_2_2747645_TEASER_11205
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 3:59 PM
$MYGN making waves with its GeneSight Psychotropic test! 🌊 📊 Meta-analysis shows MDD patients in the GeneSight arm are 41% more likely to achieve remission and 30% more likely to achieve a response compared to TAU. 📈 Long-term EPS growth rate of 33.1%, compared with industry’s 21.1%. See what this means for Myriad Genetics' stock potential 👉 https://www.zacks.com/stock/news/2747645/mygns-genesight-test-proven-superior-to-tau-stock-to-gain?cid=sm-stocktwits-2-2747645-body-11172&ADID=SYND_STOCKTWITS_TWEET_2_2747645_BODY_11172
0 · Reply
v92
v92 Sep. 5 at 11:32 AM
$MYGN what a gem!!!!
0 · Reply
v92
v92 Sep. 2 at 7:41 PM
$MYGN So someone knows something. This is a prime M&A target!!!
1 · Reply